Business
Earth Science Tech, Inc. (ETST) Announces Cancellation of 18,000,000 Common and 5,200,000 Preferred Shares, Updating the Outstanding Shares to 36,384,394 from 53,902,354
Earth Science Tech, Inc. (ETST) Announces Cancellation of 18,000,000 Common and 5,200,000 Preferred Shares, Updating the Outstanding Shares to 36,384,394 from 53,902,354.
About this update from Earth Science Tech, Inc.
[{"type":"text","content":"\n DORAL, Florida, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Earth Science Tech Inc. (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces it has canceled 18,000,000 common shares along with 5,200,000 Series A Preferred shares through a confidential settlement with Majorca LTD, the majority shareholder. The Company now has zero preferred shares outstanding and 36,384,394 common shares outstanding which is down from 53,902,354. ETST’s President, Director and Chairman Nickolas S. Tabraue stated, “We are extremely pleased to have reached a settlement with Majorca, LTD and the value it adds for our shareholders is immediately recognized and meaningful.” About Earth Science Tech Inc. (ETST) Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. Based on its studies through the University of Central Oklahoma, DV Biologics, and key organizations, ETST formulates, markets and distributes the CBD formula used for its studies to the public, offering the most effective quality of CBD on the market. To learn more, please visit: www.EarthScienceTech.com  ETST currently has two wholly owned subsidiaries and favored entity focused on developing its role as a world leader in the CBD space, expanding its work in the pharmaceutical and medical device sectors: Earth Science Pharmaceutical Inc. Earth Science Pharmaceutical (\"ESP\") is a wholly owned subsidiary of Earth Science Tech committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. Cannabis Therapeutics Inc. Cannabis Therapeutics (“CTI”) is a wholly owned subsidiary of Earth Science Tec...